MTOR and metastatic malignant neoplasm: Our study demonstrated that PI3K/AKT/mTOR pathway alterations were associated with shorter OS compared to other alterations, probably because in advanced metastatic cancer, investigational agents targeting this pathway are not as effective as those targeting other pathways; there are escape mechanisms; or there is intrinsic resistance.